Premaitha Health PLC Result of AGM (6631N)

TIDMNIPT

RNS Number : 6631N

Premaitha Health PLC

27 October 2016

Premaitha Health Plc

("Premaitha" or the "Company")

Result of AGM

Manchester, UK - 27 October 2016 - Premaitha announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed.

For more information, please contact:

 
 Premaitha Health plc                   Tel: +44 (0) 
                                         161 667 1053 
 Dr Stephen Little, Chief Executive 
  Office 
 Barry Hextall, Chief Financial 
  Officer 
 Joanne Cross, Head of Marketing 
 [e-mail] 
 
 Cairn Financial Advisers LLP (Nomad)   Tel: +44 (0) 
                                         20 7213 0880 
 Liam Murray / Jo Turner 
 
 finnCap (Broker)                       Tel: +44 (0) 
                                         20 7220 0500 
 Adrian Hargrave / Scott Mathieson 
  (Corporate Finance) 
 Tony Quirke (Corporate Broking) 
 
 Vigo Communications                    Tel: +44 (0) 
                                         20 7830 9704 
 Ben Simons / Fiona Henson / Antonia 
  Pollock 
 [e-mail] 
 

About Premaitha

Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.

Premaitha's lead test - the IONA(R) test - was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA(R) test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA(R) test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow-up diagnostic procedures which are costly, resource intensive and carry a risk of miscarriage.

Non-invasive prenatal screening is an emerging, multi-billion dollar global market and Premaitha's complete CE marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening system in-house.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGFEFFIWFMSESS

(END) Dow Jones Newswires

October 27, 2016 11:10 ET (15:10 GMT)